JP2014530009A - 異常細胞を標的とする多重特異性結合分子 - Google Patents

異常細胞を標的とする多重特異性結合分子 Download PDF

Info

Publication number
JP2014530009A
JP2014530009A JP2014533232A JP2014533232A JP2014530009A JP 2014530009 A JP2014530009 A JP 2014530009A JP 2014533232 A JP2014533232 A JP 2014533232A JP 2014533232 A JP2014533232 A JP 2014533232A JP 2014530009 A JP2014530009 A JP 2014530009A
Authority
JP
Japan
Prior art keywords
binding
proteinaceous
molecule
proteinaceous molecule
molecules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014533232A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014530009A5 (https=
Inventor
ラルフ アレキサンダー ウィレムセン，
ラルフ アレキサンダー ウィレムセン，
ヨーハン ルネ，
ヨーハン ルネ，
Original Assignee
エーピーオー‐ティー ビー．ヴイ．
エーピーオー‐ティー ビー．ヴイ．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エーピーオー‐ティー ビー．ヴイ．, エーピーオー‐ティー ビー．ヴイ． filed Critical エーピーオー‐ティー ビー．ヴイ．
Publication of JP2014530009A publication Critical patent/JP2014530009A/ja
Publication of JP2014530009A5 publication Critical patent/JP2014530009A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2014533232A 2011-09-29 2012-09-26 異常細胞を標的とする多重特異性結合分子 Pending JP2014530009A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161540920P 2011-09-29 2011-09-29
US61/540,920 2011-09-29

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017173519A Division JP2018046811A (ja) 2011-09-29 2017-09-08 異常細胞を標的とする多重特異性結合分子

Publications (2)

Publication Number Publication Date
JP2014530009A true JP2014530009A (ja) 2014-11-17
JP2014530009A5 JP2014530009A5 (https=) 2017-01-19

Family

ID=47018432

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014533232A Pending JP2014530009A (ja) 2011-09-29 2012-09-26 異常細胞を標的とする多重特異性結合分子
JP2017173519A Pending JP2018046811A (ja) 2011-09-29 2017-09-08 異常細胞を標的とする多重特異性結合分子
JP2019211793A Pending JP2020058354A (ja) 2011-09-29 2019-11-22 異常細胞を標的とする多重特異性結合分子

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2017173519A Pending JP2018046811A (ja) 2011-09-29 2017-09-08 異常細胞を標的とする多重特異性結合分子
JP2019211793A Pending JP2020058354A (ja) 2011-09-29 2019-11-22 異常細胞を標的とする多重特異性結合分子

Country Status (6)

Country Link
US (3) US11098115B2 (https=)
EP (2) EP2760892A1 (https=)
JP (3) JP2014530009A (https=)
AU (3) AU2012316859A1 (https=)
CA (1) CA2850291A1 (https=)
WO (1) WO2013048243A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024504903A (ja) * 2021-01-29 2024-02-02 中外製薬株式会社 細胞死が観察される組織において特異的に作用する分子

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012091564A2 (en) * 2010-12-27 2012-07-05 Apo-T B.V. A cross-linking polypeptide that induces apoptosis
EP2760892A1 (en) 2011-09-29 2014-08-06 Apo-T B.V. Multi-specific binding molecules targeting aberrant cells
AU2013208364B2 (en) 2012-01-13 2017-10-26 Apo-T B.V. Aberrant cell-restricted immunoglobulins provided with a toxic moiety
EP2864354A1 (en) * 2012-06-26 2015-04-29 Apo-T B.V. Binding molecules targeting pathogens
WO2016077720A1 (en) * 2014-11-14 2016-05-19 Protein One, Llc Binding agents and uses thereof
TWI603980B (zh) * 2015-09-01 2017-11-01 免疫功坊股份有限公司 用以治療病理性血栓的聯合接合物構型藥物
MA43874A (fr) * 2016-01-13 2018-11-21 Compass Therapeutics Llc Constructions de liaison à l'antigène immunomodulateur multispécifique
AU2019283639A1 (en) * 2018-06-04 2021-01-07 Apo-T B.V. Methods and means for attracting immune effector cells to tumor cells
IL322315A (en) 2019-05-14 2025-09-01 Provention Bio Inc Methods and preparations for preventing type 1 diabetes
DE102019121007A1 (de) * 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Antigenbindende Proteine, die spezifisch an MAGE-A binden
AU2021287998B2 (en) 2020-06-11 2026-03-12 Benaroya Research Institute At Virginia Mason Methods and compositions for preventing type 1 diabetes
WO2021263221A1 (en) * 2020-06-26 2021-12-30 Novather, Inc. Binding modulator
US11912771B2 (en) 2021-03-09 2024-02-27 Cdr-Life Ag MAGE-A4 peptide-MHC antigen binding proteins
EP4304725A1 (en) 2021-03-09 2024-01-17 CDR-Life AG Rabbit-derived antigen binding protein nucleic acid libraries
US12162940B2 (en) 2021-05-05 2024-12-10 Immatics Biotechnologies Gmbh BMA031 antigen binding polypeptides
US12565529B2 (en) 2021-05-24 2026-03-03 Provention Bio, Inc. Methods for treating type 1 diabetes
KR20250067130A (ko) 2022-09-14 2025-05-14 씨디알-라이프 아게 Mage-a4 펩티드 이중 t 세포 연결체
CN120359047A (zh) * 2022-10-14 2025-07-22 旗舰创业创新第七有限责任公司 用于靶向递送治疗剂的组合物和方法
CN119529098B (zh) * 2025-01-22 2025-05-30 北京可瑞生物科技有限公司 对mage-a1具有特异性的结合分子和抗cd3的融合蛋白

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003525016A (ja) * 1998-02-19 2003-08-26 エクサイト セラピーズ， インコーポレイテッド リンパ球活性化を調節するための組成物および方法
JP2005501517A (ja) * 2001-04-11 2005-01-20 中国科学院遺▲傳▼学研究所 環状一本鎖三重特異性抗体
JP2005504524A (ja) * 2001-06-28 2005-02-17 ドマンティス リミテッド 二重特異性リガンドとその利用
JP2009515897A (ja) * 2005-11-10 2009-04-16 キュラジェン コーポレイション Ｔ細胞の免疫グロブリンドメインおよびムチンドメイン１（ｔｉｍ−１）抗原に対する抗体を用いて卵巣癌および腎臓癌を処置する方法
JP2009524422A (ja) * 2006-01-25 2009-07-02 エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム 結合分子３
JP2010535032A (ja) * 2007-07-31 2010-11-18 メディミューン，エルエルシー 多重特異性エピトープ結合性タンパク質およびその用途
JP2014505471A (ja) * 2010-12-27 2014-03-06 エーピーオー‐ティー ビー．ヴイ． アポトーシスを誘導する架橋ポリペプチド

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB601513A (en) 1946-02-06 1948-05-06 Koray Ltd Improvements in or relating to coated tissue especially paper and to coating compositions therefor
DE321017C (https=) 1917-05-15 1920-05-11 Aloysius Petrus Van Leuven
US3687370A (en) 1971-01-18 1972-08-29 Instapak Corp Liquid mixing and dispensing apparatus
NL9001639A (nl) 1990-07-19 1992-02-17 Amc Amsterdam Pt-houdende verbinding, werkwijze voor de bereiding ervan, alsmede toepassing van dergelijke verbindingen.
US5709995A (en) 1994-03-17 1998-01-20 The Scripps Research Institute Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses
PT1019420E (pt) 1995-05-09 2003-12-31 Kreatech Biotech Bv Metodos para a producao de ligandos baseados em platina para ligacao entre marcadores e moleculas bio-orgaicas na marcacao de moleculas bio-organicas com o fim de detectar substancias biologicas de interesse e conjuntos ("kits") de ensaios de diagnosticos
EP0973785B1 (en) 1997-04-10 2003-12-03 Kreatech Biotechnology B.V. Trans-platinum compound, and diagnostic kit
CZ299874B6 (cs) 1997-08-12 2008-12-17 Leadd B. V. Zpusob urcení transformacní schopnosti cinidel, zpusob urcení predispozice bunky, zpusob zjištení genové mutace, použití nukleové kyseliny kódující apoptin a diagnostická testovací souprava
ES2293748T3 (es) 1998-10-21 2008-03-16 Altor Bioscience Corporation Moleculas de fijacion poliespecificas y usos de las mismas.
IL127142A0 (en) 1998-11-19 1999-09-22 Yeda Res & Dev Immune cells having predefined biological specificity
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7527787B2 (en) 2005-10-19 2009-05-05 Ibc Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
AU2002246455A1 (en) 2001-03-30 2002-10-15 Leadd B.V. Fusion proteins for specific treatment of cancer and auto-immune diseases
JP4049297B2 (ja) 2001-06-11 2008-02-20 株式会社ルネサステクノロジ 半導体記憶装置
US20100081792A1 (en) * 2001-06-28 2010-04-01 Smithkline Beecham Corporation Ligand
GB0115841D0 (en) 2001-06-28 2001-08-22 Medical Res Council Ligand
EP1433793A4 (en) * 2001-09-13 2006-01-25 Inst Antibodies Co Ltd METHOD FOR CREATING A CAMEL ANTIBODY LIBRARY
WO2003040722A1 (en) 2001-11-09 2003-05-15 Kreatech Biotechnology B.V. Means and methods for the detection of immunoglobulin capable of binding to mycobacterium antigen
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
AU2003216341A1 (en) 2002-02-20 2003-09-09 Dyax Corporation Mhc-peptide complex binding ligands
FR2837837B1 (fr) 2002-03-28 2006-09-29 Roussy Inst Gustave Epitopes peptidiques communs a des antigenes d'une meme famille multigenique
AU2003214721A1 (en) 2002-04-19 2003-11-03 Leadd B.V. Fragments of apoptin
ES2263984T3 (es) 2002-06-28 2006-12-16 Domantis Limited Ligandos doble-especificos con una vida media serica aumentada.
US7820166B2 (en) * 2002-10-11 2010-10-26 Micromet Ag Potent T cell modulating molecules
JP2006523437A (ja) 2002-12-03 2006-10-19 アヴィデックス リミテッド レセプター複合体
DK1613750T3 (en) * 2003-03-19 2016-01-18 Amgen Fremont Inc ANTIBODIES TO T CELL AND MUCINDO immunoglobulin-binding domain 1 (TIM-1) antigen and uses thereof
CA2522586C (en) * 2003-05-31 2017-02-21 Micromet Ag Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
SI1629011T1 (sl) * 2003-05-31 2010-05-31 Micromet Ag Humane molekule za vezavo anti hu cd
ES2296423B1 (es) * 2003-07-31 2009-03-16 Consejo Sup. Investig. Cientificas Construccion de adn para la produccion de proteinas de fusion dimericas y sus aplicaciones.
US20050026881A1 (en) 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-IgE antibody for treatment of asthma or chronic obstructive pulmonary disease
US7488793B2 (en) * 2003-09-22 2009-02-10 Ludwig Institute For Cancer Research Isolated peptide which binds to HLA-Cw*07 and uses thereof
SI2295073T1 (sl) 2003-11-17 2014-07-31 Genentech, Inc. Protitelo proti CD22 za zdravljenje tumorja hematopoetskega izvora
NZ547157A (en) 2003-12-10 2009-07-31 Medarex Inc Interferon Alpha Antibodies and their uses
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
EP1696963A2 (en) 2003-12-24 2006-09-06 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
US20050266425A1 (en) * 2003-12-31 2005-12-01 Vaccinex, Inc. Methods for producing and identifying multispecific antibodies
DK1765860T3 (da) 2004-05-19 2009-03-09 Immunocore Ltd Ny-ESO-T.cellereceptor med höj affinitet
JP2008501781A (ja) 2004-06-09 2008-01-24 テクニオン リサーチ アンド ディベロップメント ファウンデーション リミテッド 細胞の選択的アポトーシスのための抗体
AU2005291039A1 (en) * 2004-10-01 2006-04-13 Avidex Ltd. T-cell receptors containing a non-native disulfide interchain bond linked to therapeutic agents
CA2634292A1 (en) * 2005-12-20 2007-06-28 Erasmus University Medical Center Rotterdam Apoptosis-inducing protein complexes and therapeutic use thereof
JP2009521474A (ja) * 2005-12-21 2009-06-04 メディミューン，エルエルシー ＥｐｈＡ２ＢｉＴＥ分子およびその使用
AT503902B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von immunglobulinen
CA2682093A1 (en) 2007-03-29 2008-10-09 Technion Research & Development Foundation Ltd. Antibodies, methods and kits for diagnosing and treating melanoma
WO2008119566A2 (en) * 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific bispecific binders
ES2447844T3 (es) 2008-04-03 2014-03-13 Vib Vzw Anticuerpos de dominio individual capaces de modular la actividad BACE1
WO2009131435A1 (en) 2008-04-23 2009-10-29 Erasmus University Medical Center Rotterdam Linker containing bungarotoxin and a binding peptide
BRPI0913366A8 (pt) 2008-06-03 2017-07-11 Abbott Lab Imunoglobulinas de domínio variável duplo e seus usos
CA2738568C (en) * 2008-10-01 2024-02-20 Micromet Ag Cross-species-specific single domain bispecific single chain antibody
CN102282168A (zh) 2008-11-18 2011-12-14 梅里麦克制药股份有限公司 人血清白蛋白接头以及其结合物
EP3470425A3 (en) 2008-12-19 2019-07-17 Ablynx N.V. Immunoglobulins against cell-associatd antigens such as p2x7
GB0908613D0 (en) * 2009-05-20 2009-06-24 Immunocore Ltd T Cell Reseptors
TW201100543A (en) 2009-05-27 2011-01-01 Hoffmann La Roche Tri-or tetraspecific antibodies
GB0911566D0 (en) * 2009-07-03 2009-08-12 Immunocore Ltd T cell receptors
ES2688978T3 (es) * 2009-11-23 2018-11-07 Amgen Inc. Anticuerpo monomérico Fc
WO2011064664A2 (en) 2009-11-24 2011-06-03 Chrontech Pharma Ab T cell receptors specific for immunodominant ctl epitopes of hcv
US20130131088A1 (en) 2010-01-13 2013-05-23 University Health Network Treating cancer with statins and compounds having dipyridamole activity
US20120123218A1 (en) 2010-11-16 2012-05-17 JPWaVe BV Methods and means for clinical investigations
US9821073B2 (en) 2010-12-27 2017-11-21 Apo-T B.V. Polypeptide that binds aberrant cells and induces apoptosis
EP2760892A1 (en) 2011-09-29 2014-08-06 Apo-T B.V. Multi-specific binding molecules targeting aberrant cells
AU2013208364B2 (en) 2012-01-13 2017-10-26 Apo-T B.V. Aberrant cell-restricted immunoglobulins provided with a toxic moiety
EP2864354A1 (en) 2012-06-26 2015-04-29 Apo-T B.V. Binding molecules targeting pathogens

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003525016A (ja) * 1998-02-19 2003-08-26 エクサイト セラピーズ， インコーポレイテッド リンパ球活性化を調節するための組成物および方法
JP2005501517A (ja) * 2001-04-11 2005-01-20 中国科学院遺▲傳▼学研究所 環状一本鎖三重特異性抗体
JP2005504524A (ja) * 2001-06-28 2005-02-17 ドマンティス リミテッド 二重特異性リガンドとその利用
JP2009515897A (ja) * 2005-11-10 2009-04-16 キュラジェン コーポレイション Ｔ細胞の免疫グロブリンドメインおよびムチンドメイン１（ｔｉｍ−１）抗原に対する抗体を用いて卵巣癌および腎臓癌を処置する方法
JP2009524422A (ja) * 2006-01-25 2009-07-02 エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム 結合分子３
JP2010535032A (ja) * 2007-07-31 2010-11-18 メディミューン，エルエルシー 多重特異性エピトープ結合性タンパク質およびその用途
JP2014505471A (ja) * 2010-12-27 2014-03-06 エーピーオー‐ティー ビー．ヴイ． アポトーシスを誘導する架橋ポリペプチド

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SEGAL, DM., ET AL.: "Introduction: bispecific antibodies", JOURNAL OF IMMUNOLOGICAL METHODS, vol. 248, JPN6016025423, 2001, pages 1 - 6, ISSN: 0003349771 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024504903A (ja) * 2021-01-29 2024-02-02 中外製薬株式会社 細胞死が観察される組織において特異的に作用する分子

Also Published As

Publication number Publication date
CA2850291A1 (en) 2013-04-04
AU2020200888A1 (en) 2020-02-27
JP2020058354A (ja) 2020-04-16
US11098115B2 (en) 2021-08-24
AU2012316859A1 (en) 2014-04-17
WO2013048243A1 (en) 2013-04-04
US20140227273A1 (en) 2014-08-14
JP2018046811A (ja) 2018-03-29
EP3388451A1 (en) 2018-10-17
AU2017248425A1 (en) 2017-11-02
AU2017248425B2 (en) 2019-11-14
US20250115662A1 (en) 2025-04-10
EP2760892A1 (en) 2014-08-06
US20210355209A1 (en) 2021-11-18

Similar Documents

Publication Publication Date Title
US20250115662A1 (en) Multi-specific binding molecules targeting aberrant cells
US11578126B2 (en) Chimeric antigen receptor (CAR) comprising a CD19-binding domain
US20260078166A1 (en) Anti-dll3 chimeric antigen receptors and uses thereof
CN111699201B (zh) 抗pd-1/抗her2天然抗体结构的异源二聚双特异性抗体及其制备方法
WO2022222910A1 (zh) 靶向gprc5d的抗体及其用途
WO2022247795A1 (zh) 靶向Claudin18.2的纳米抗体及其用途
WO2022111405A1 (zh) 靶向Claudin18.2的抗体及其用途
WO2024001470A1 (zh) 靶向b7-h3的抗体及其用途
Hayashi et al. A highly effective and stable bispecific diabody for cancer immunotherapy: cure of xenografted tumors by bispecific diabody and T-LAK cells
KR102829757B1 (ko) 인간화된 cd22에 특이적인 항체 및 이를 이용한 키메라 항원 수용체
KR102393776B1 (ko) Cd22에 특이적인 인간화 항체 및 이를 이용한 키메라 항원 수용체
WO2023163087A1 (ja) 抗変異ｃａｌｒ抗体と他の薬剤とを組み合わせてなる医薬
EP4606823A1 (en) Synthetic t cell receptor antigen receptor specifically binding to lilrb4 and use thereof
US20250136695A1 (en) Development of novel pdl1 single-domain antibody
NZ739019A (en) Multi-specific binding molecules targeting aberrant cells
WO2024239143A1 (zh) 工程化细胞及其用途
WO2026040975A1 (zh) 靶向cd33的抗体及其用途

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150901

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160623

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160705

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161005

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20161202

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170509